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Summary The concentration of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) was determined in the
serum of 90 untreated and 42 treated metastatic cancer patients, including patients with colorectal, breast, ovarian and renal carcinomas,
with an enzyme-linked immunosorbent assay (ELISA). Levels higher than the 95th percentile of the concentrations of a control group, i.e.
7.5 pg ml-' for bFGF and 500 pg ml-1 for VEGF, were identified as 'elevated'. One measurement during follow-up was included into the
analysis per patient. For 19 treated patients, consecutive serum samples were analysed. Fifty-seven per cent of all untreated patients had
elevated serum levels of one or both angiogenic factors. The fraction of patients with elevated serum levels of bFGF and/or VEGF was similar
in the different tumour types. Agreement of bFGF levels and VEGF levels, classified in relation to their respective cut-off values, was present
in 67% of all patients. Fifty-eight per cent of the patients with progressive disease during treatment compared with 15% of the patients
showing response to treatment (chi-squared test P< 0.05) had elevated bFGF and/or VEGF serum levels. When consecutive serum samples
were analysed, two-thirds of the patients showing progressive disease had increasing serum levels of the angiogenic factors compared with
less than one-tenth ofthe patients showing response (chi-squared test P< 0.05). The lack of association between the serum bFGF and VEGF
levels and the tumour type may suggest an aspecific host reaction responsible for solid tumour-related angiogenesis. The main determinants
of the serum bFGF and VEGF concentration are the progression kinetics of the metastatic carcinomas.
Keywords: angiogenesis; solid tumours; basic fibroblast growth factor; vascular endothelial cell growth factor; enzyme-linked
immunosorbent assay
Urine and other body fluids ofcancer patients have been shown to
contain endothelial chemokinetic and proliferative activity
(Chodak et al, 1981, 1988; Li et al, 1994). After the development
of sensitive enzyme immunoassays for bFGF (Watanabe et al,
1991) and VEGF (Kondo et al, 1994), elevated levels of both
angiogenic factors have been detected in the serum and the urine
of patients with various types of cancer (Nguyen et al, 1994;
Yamamoto et al, 1996) and have been detected significantly less
frequently in individuals with no sign of cancer, ongoing inflam-
mation or wound healing. This suggests that the induction of
angiogenesis in human cancer is at least partly mediated by bFGF
and VEGF.
New vessel development is required for tumour cell prolifera-
tion, extracellular matrix invasion and haematogenous metastasis
(Folkman, 1990). The extent of the vasculature assessed by
immunohistochemistry and microvessel counting predicts prog-
nosis in many tumour types (Weidner et al, 1996).
bFGF and VEGF are two potent heparin-binding mediators
of angiogenesis with a synergistic effect in vitro (Goto et al,
1993) and in vivo (Asahara et al, 1995). Both angiogenic factors
are involved in an autocrine endothelial cell mitogenic loop
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(Schweigerer et al, 1987; Liu et al, 1995). VEGF receptors are
expressed only on endothelial cells (Keck et al, 1989). Low
oxygen tension induces the expression of bFGF and VEGF in
host-derived cells and in tumour cells (Shweiki et al, 1992;
Kuwabara et al, 1995).
There is a lack of quantitative data comparing the serum
concentration of bFGF and VEGF in cancer patients. We initiated
a study using two commercially available ELISA kits to investi-
gate the association ofserum bFGF and VEGF levels with clinical
parameters ofdisease progression kinetics in untreated and treated
metastatic breast, colorectal, ovarian and renal adenocarcinoma
patients. Our results are discussed and compared with previously
published data on serum bFGF and VEGF measurements.
MATERIALS AND METHODS
FromJanuary 1995 on, serum samples were takenfrom 146 patients.
In 14 operable colon cancer patients, samples were collected before
and one month after surgery and from 132 patients who had devel-
oped distant metastasis during follow-up. Out ofthese 132 patients,
42patients received some form ofchemo- orhormonotherapy during
the follow-up period. In 16 of these treated metastatic patients, a
colorectal adenocarcinoma hadbeendiagnosed, in 17 abreastadeno-
carcinoma, in six an ovarian and in three a renal adenocarcinoma. Of
the 90 untreated patients, 46 had a colorectal adenocarcinoma, 22 a
breast adenocarcinoma, 10 an ovarian and 12 a renal carcinoma. Ten
millilitres of venous blood was drawn into a serum separator tube
(type vacutainer code 607213 Becton-Dickinson) and immediately
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Figure 1 Correlation of serum bEGE and VEGF levels of 121 patients. Each
dot represents the bEGE and VEGE serum level of one patient (simple linear
regression: r= 0.21; P= 0.02). All samples were obtained before the
initiation of any form of therapy
centrifuged at 3000 r.p.m. for 10 min. Thereafter the serum was sepa-
rated and aliquoted in 1.0-mi fractions and stored at-80°C. Patient
follow-up information was entered into a computerized database.
To analyse the effect of tumour progression on the bFGF and
VEGF serum levels, the progression kinetics were determined in
89 out of the 132 patients with metastatic disease, based on radio-
logical documents or, for ovarian cancer, on CA125 serum levels,
both taken at least within a 3-month interval. Rapid progression
was defined as a doubling within 6 months or less ofthe product of
the largest perpendicular diameters of any measurable metastatic
lesion, measured either on plain film or computerized tomography
images, or as a doubling of the CA125 serum level within 3
months or less. Patients receiving treatment and having a response
or a stable disease were excluded from this part of the analysis.
Nineteen of the 89 patients progressed under treatment.
For the analysis of the effect of treatment on bFGF and VEGF
serum levels, World Health Organization (WHO) criteria for
response, no change and progressive disease were used. Tumour
response was defined as a decrease in the product of the largest
perpendicular tumour diameters or in the CA125 serum level of at
least 50%. Progressive disease was present if the values of the
parameters had increased by 25% or more. All other situations
were categorized as a no change.
Successive serum levels of bFGF and VEGF were determined
during the follow-up period (mean duration of 11.3 months;
median 11.8 months) using two ELISA kits of R&D Systems,
Minneapolis, MN, USA (Quantikine High Sensitivity human FGF
basic and Quantikine human VEGF). Within-assay reproducibility
was evaluated on duplicates in a subset of 115 samples. Elevated
bFGF and VEGF levels were defined as being greater than the
95th percentile value in the normal control subject group described
by R&D Systems. This resulted in a cut-off value for bFGF of
7.5 pg ml l and for VEGF of 500 pg mll.When classified in rela-
tion to the cut-off value, accordance was present in 85% of the
patients for successive bFGF serum levels during the follow-up
period. The same accordance rate was obtained for VEGF. The
value of the first measurement done during the follow-up period
was therefore taken for further analysis. Such a bFGF serum
concentration value was available for 123 patients. A VEGF serum
concentration value was available for 129 patients. In 121 patients,
serum levels ofboth angiogenic factors were available.
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Figure 2 bFGF (n= 13) and VEGF (n= 14) pre- and post-operative serum
levels in colorectal cancer patients
In 12 treated colorectal and seven treated breast adenocarci-
noma patients, successive serum concentrations were used for
further analysis.
Statistical analysis was performed with the Statview 4.0
statistical software application (Abacus Concepts) on an Apple
Macintosh personal computer. The correlation between bFGF and
VEGF serum concentration in the same sample was analysed by a
simple linearregression model. Comparison ofpre- and post-oper-
ative levels of bFGF and VEGF was performed using a Wilcoxon
ranking test. The difference in the fraction of patients with
elevated serum bFGF or VEGF levels in the groups investigated
was analysed by a Chi-squared test. Mean bFGF and VEGF serum
levels were compared using a Mann-Whitney U-test. A P-value
< 0.05 was considered to be significant.
RESULTS
When VEGF serum levels were determined in duplicate, 96% (110
of 115 samples) of the results had a coefficient of variation of less
than 10%, and 61% (70 of 115 samples) had a coefficient ofvaria-
tion ofless than 5%. For bFGF, the respective fractions were 73%
(78 of 107 samples) and 41% (44 of 107 samples). Agreement of
bFGF and VEGF serum levels when classified according to the
respective cut-offvalues perpatient was present in 67% (81 of 121
patients) of the patients. A significant, though weak, correlation
was found between absolute bFGF and VEGF serum levels
(n = 121; r = 0.21; P <0.05) (Figure 1).
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Figure 3 Comparison of VEGF (n = 88) and bFGF (n = 83) serum levels according to the tumour type in the group of untreated metastatic tumour patients.
Mean and standard deviation are shown by the bars. In the bars the mean ± standard deviation(median) serum level is given for each tumour. The fractions of
patients with serum levels of bFGF, VEGF and of VEGF and/or bFGF above the respective cut-off value forthe different tumourtypes are given in the boxes:
number of patients with elevated serum level(s)/total number (percentage). No differences were present between the tumourtypes (P > 0.05: Mann-Whitney
U-test and chi-squared test)
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Figure 4 Comparison of VEGF and bFGF serum levels according to response to chemo-, hormonotherapy (n = 41; 15 colorectal, 18 breast, six ovarian and two
renal cancer patients). Each dot represents the serum level of one patient. The values indicate the fraction of patients with a VEGF or bFGF serum level above
the cut-off of 500 pg ml-' and 7.5 pg ml-' respectively. The boxes above the graphs indicate the mean ± standard deviation(median) of the serum levels (pg ml-')
of the respective patient groups. Indicates a P-value of 0.025 and ** a P-value of 0.004 related to the differences of the mean values analysed by
Mann-Whitney U-test. *Indicates a P-value of 0.025 of the difference in distribution between both groups marked, analysed with Fisher's exact chi-squared test
The majority ofthe patients with elevated preoperative bFGF or
VEGF serum levels had normalized levels 1 month after surgery
(Figure 2). Mean preoperative bFGF levels were 11.4 pg ml-1
(standard deviation 10.6; median 8.8; n = 13). Post-operative
bFGF levels were significantly lower (Wilcoxon ranking test
P < 0.05) (mean 6.4 pg ml-'; standard deviation 6.4; median 4.3).
Mean preoperative VEGF levels were 479 pg ml-1 (standard devi-
ation 461; median 325; n = 14). Post-operative VEGF levels were
not significantly lower (Wilcoxon ranking test P = 0.1) (mean
311 pg ml-'; standard deviation 233; median 223). Only one
patient had a normal preoperative serum level (VEGF), which
was elevated after surgery. The patient with an elevated VEGF
serum level (666 pg ml-) before surgery and a higher still level
(965 pg ml-') after surgery had developed a gastric ulcer in the
period between the two measurements.
When all the untreated metastatic cancerpatients were analysed,
57% (46 of 81 patients) had an elevated serum level of at least one
of the angiogenic factors. For bFGF, 40% (33 of 83 patients) and
for VEGF 40% (35 of 88 patients) had an elevated serum level.
bFGF serum levels ranged from 0.0 pg mll to 33.0 pg ml' (n = 83;
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mean 9.0; standard deviation 9.7; median 5.1). VEGF serum levels
ranged from 40 pg ml-' to 1650 pg ml-' (n = 88; mean 452; stan-
dard deviation 322; median 367 pg ml-'). There was no difference
in the fraction of patients with elevated serum levels, nor in the
mean serum levels, when the tumour types were compared
(Figure 3). The difference in the fraction of breast cancer patients
with an elevated bFGF serum level (58%) and colorectal cancer
patients with an elevated bFGF serum level (33%) showed a trend
towards significance (chi-squared test P = 0.06).
Fifty-five per cent of the patients (49 of 89 patients) for whom
the tumour progression rate could be estimated were defined as
having a rapid progression of disease. The other 40 patients were
categorized as the slowly progressive group. Of the patients with
rapid progression, 93% (40 of 43 patients) had elevated serum
levels of bFGF and/or VEGF compared with only 13% (5 of 38
patients) in the other group (Chi-squared test P < 0.0001). The
corresponding fractions for bFGF alone were 72% vs 3% and
for VEGF alone were 63% vs 15% (Chi-squared test P < 0.0001).
The mean bFGF serum level in the fast-progression group was
14.7 pg ml-' (standard deviation 10.2; range 0.3-33.0; median
10.7 pg ml-') vs 2.9 pg ml-' in the slow-progression group (stan-
dard deviation 2.1; range 0.1-9.4; median 2.6 pg ml-') (Mann-
Whitney U-test P < 0.0001). The mean VEGF serum level in the
fast-progression group was 619 pg ml-' (standard deviation 381;
range 40-1650; median 597 pg ml-') vs 324 pg ml-' in the slow-
progression group (standard deviation 195; range 70-999; median
289 pg ml-') (Mann-Whitney U-test P < 0.0001).
Patients receiving chemo- or hormonotherapy and having a
progressive disease had higher bFGF serum levels than the
patients showing tumour response, and a larger fraction of the
former group had elevated bFGF and/or VEGF serum levels
(Figure 4 and Table 1).
When consecutive serum samples were analysed in the 19
treated patients, 63% (5 of8 patients) with progressive disease had
increasing levels during follow-up ofat least one ofthe angiogenic
factors compared with 9% (1 of 11 patients) in the responding
patients (continuity corrected chi-squared test P < 0.05). Decreas-
ing levels were found in 0% (0 of 8 patients) of the progressive
disease group compared with 55% (6 of 11 patients) of the
responding patients (chi-squared test, Fisher's Exact P < 0.05).
DISCUSSION
We present quantitative data on the concentration of serum bFGF
and VEGF in 132 patients with metastatic tumours of various
histologies and in 14 patients with operable colorectal carcinoma,
using an ELISA method. Elevated preoperative angiogenic factor
serum levels were normalized after surgery in most ofthe patients.
Our main observations in the patients with advanced carcinomas
were the lack ofcorrelation ofbFGF and VEGF serum levels with
the tumour type and the strong correlation of serum levels ofboth
angiogenic factors with tumour progression kinetics.
Four out of ten untreated metastatic cancer patients had an
elevated bFGF serum level and the same fraction had an elevated
VEGF serum level. About 60% of all untreated patients had
elevated serum levels of one or both angiogenic factors. This frac-
tion was raised to more than 90% when only patients with rapid
progressive disease, including patients receiving treatment, were
considered. Mean bFGF serum levels were five times higher in the
fast-progression patient group than in the slow-progression group.
A twofold difference in favour of the former group was observed
for VEGF serum levels.
Removal of a primary colorectal adenocarcinoma clearly
decreased the individual serum levels of bFGF and VEGF. This
suggests that the source ofboth angiogenic factors is present in the
tumour tissue. The same observation has been made for VEGF by
Yamamoto et al (1996) and for bFGF by Sliutz et al (1995) in
primary breast cancer.
Nguyen et al (1994) have measured bFGF levels in the urine of
patients with different types of solid tumours. Elevated bFGF was
defined as a urinary level greater than the 90th percentile level of
normal control subjects. The fraction of patients with elevated
urinary bFGF was 45% in the metastatic patient group compared
with 31% in the group of patients with local tumour growth. The
proportions of patients with elevated urinary bFGF levels were
similar in the different histology groups. Yamamoto et al (1996)
have compared serum VEGF levels in 241 patients with mainly
primary or recurrent breast and gastric cancer using an enzymatic
immunoassay. The cut-off level was calculated as the 95th
percentile of the level of normal controls. The rate of elevation of
the VEGF serum levels was not related to the tumour type and
averaged 15%. When recurrent breast cancer patients were
analysed separately, 29% had high circulating VEGF levels, a
fraction similar to our result of38% in the metastatic breast cancer
patient group. Toi et al (1996) measured intratumoral protein
levels of VEGF in 135 primary breast cancers. They observed a
wide variation in VEGF content and a significant relationship
between the tumour VEGF concentration and the microvessel
density as determined by immunohistochemical vessel counting.
Berger et al (1995) studied the expression of VEGF mRNA in 65
human tumour xenografts of various histologies in athymic nude
mice. The major disadvantage of the model is that only human
tumour cell-derived VEGF mRNA was measured, and thus the
host stromal response was neglected. High expression was defined
as being at least 20% of the expression level of a positive control
prostate cancer. High expression levels were observed in 34% of
all xenografts. VEGFmkNA content ofthe xenografts was similar
in all tumour types with the exception of renal cell carcinomas.
Seven out of a total of 10 renal cell carcinoma xenografts exhib-
ited ahigh VEGF mRNA expression. In our study, metastatic renal
cancer patients had the highest absolute serum bFGF and VEGF
levels. The fraction of renal cancer patients with at least one or
both angiogenic factor serum levels elevated was also up to 14%
higher than in the cancer patients with othertumours. These differ-
ences were not significant.
Table 1 Comparison of the fraction of patients with bFGF and/or VEGF
serum levels above the respective cut-off levels according to response to
chemotherapy (n = 41: 15 colorectal, 18 breast, six ovarian and two renal
cancer patients)
bFGF and/or VEGF serum levels above cut-off
Progression 11/19 (58)a
P= 0.070
No change 2/9 (22)
P= 0.013
Response 2/13 (15)
aNumber of patients with elevated level(s) / total number (percentage).
P-values are related to chi-squared tests.
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The lack of difference in bFGF and VEGF levels measured in
body fluids and tumour tissue between patients with various
tumour types might indicate that host characteristics prevail on the
tumour cell phenotype in determining the extent of angiogenesis.
A discrepancy between the amount of bFGF produced by a
colorectal adenocarcinoma cell line in vitro and by xenografted
tumours derived from the same cell line has recently been reported
(McCarty et al, 1995). The increase in bFGF levels in vivo resulted
primarily from the presence of 40% of host cells within the
xenografted neoplasms. Different stromal cell types have been
found to express angiogenesis-modulating factors in different
tumour types (reviewed in Leek et al, 1994).
The positive association of the high progression rate of the
metastatic lesions with the circulating levels of bFGF and VEGF
indirectly supports the hypothesis stated by Folkman et al (1990)
that tumour growth is dependent on angiogenesis. bFGF and
VEGF are potent and synergistically acting cytokines with proven
angiogenic activity both in vitro and in vivo (Goto et al, 1993;
Asahara et al, 1995). The tumour cell proliferation fraction is one
ofthe factors contributing to tumour volume increase and has been
related to bFGF and VEGF expression in several studies. In histo-
logical sections of head and neck squamous cell carcinomas, the
tumour cell bromodeoxyuridine labelling index was five times
higher in the bFGF-positive areas than in the bFGF-negative areas
(Schultz-Hector et al, 1993). Endothelial cell labelling indices were
associated with regional differences in bFGF expression in the
same way as in a murine squamous cell carcinoma model.
Endothelial cell doubling times were about 2.5 times shorter in the
bFGF-positive tumour regions. In a series of 52 colon adenocarci-
nomas, the intensity of VEGF immunostaining, but not of bFGF
immunostaining, correlated with the fraction of proliferating cell
nuclear antigen (PCNA)-positive tumour cell nuclei in the sections
(Takahashi et al, 1995). The intensity of staining of VEGF and
bFGF was graded on a scale from 0 to 3. Proliferation was evalu-
ated by counting the fraction of PCNA-positive staining tumour
cells at the invasive edge. Also, in a series of 91 epidermoid lung
carcinomas, a close correlation of VEGF expression with tumour
cell proliferation was found (Mattem et al, 1996). In colorectal
adenocarcinomas, Vermeulen et al (1995) have reported an intra-
tumoral topographical correlation between microvessel density,
Ki67 endothelial cell labelling index and Ki67 tumour cell labelling
index. The finding of a positive association ofmicrovessel density
and tumour cell proliferation was supported in another study on
colon cancer (Takahashi et al, 1995) but not in breast cancer (Fox et
al, 1993) nor in lung cancer (Mattern et al, 1996).
We have recently reported that the positive association ofa short
tumour volume-doubling time with elevated bFGF and VEGF
serum levels in advanced colorectal cancer is largely independent
of the metastatic pattern and the extent of the disease (Dirix et al,
1996). The observation that most of the patients with progressive
disease during treatment have increasing angiogenic factor serum
levels might indicate that there is a minor effect oftumour mass.
Data for sarcomas and lymphomas, two tumour types for which
grade reliably predicts the course of clinical progression, confirm
the results of this study. Patients with high-grade malignancies,
being characterized by fast progression, were found to have about
five times higher bFGF and VEGF serum levels than the patients
with low-grade sarcomas or lymphomas (Dirix et al, 1996).
The level of bFGF and VEGF expression had an impact on the
survival of the cancer patients included in the studies of Nguyen et
al (1994) and Berger et al (1995). Survival among cancer patients at
the median follow-up time was 85% for individuals with a normal
urinary bFGF concentration compared with 71% for individuals
with an elevated bFGF level (Kaplan-Meier analysis, P = 0.0007).
In the study ofBerger et al (1995) measuring mRNA expression of
VEGF in human tumour xenografts obtained from 65 patients with
different histologies, the overall 5-year survival was about 20%
lower in the high-VEGF expression group compared with the low-
VEGF expression group. Serum VEGF concentration in 137 breast
cancerpatients was associated with microvessel density (Yamamoto
et al, 1996). In thepatients with less than 100microvessels permm2,
only 2.9% had an elevated serum VEGF. In those with more than
150 microvessels per mm2, 42.9% had an elevated serum VEGF.
Indirectly, VEGF serum levels might thus be related with prognosis
as high microvessel density has been associated with shortened
survival in many studies (Gasparini et al, 1995).
The positive association of bFGF and VEGF expression with
tumour and endothelial cell proliferation, with tumour growth
kinetics in treated and untreated patients and with early relapse
warrants a prospective controlled study to investigate the value of
the angiogenic profile of an individual cancer patient to predict
outcome and response to therapy. More than halfofthe metastatic
patients and almost all patients showing fast progression had high
circulating levels of at least one of the two angiogenic factors
studied. The design of an anti-angiogenic treatment directed at
blocking the action ofbFGF orVEGF might therefore be a reason-
able therapeutic approach. Given the high degree of agreement
(67%) between elevated bFGF and VEGF levels in the metastatic
patient group, a combined anti-bFGF and anti-VEGF treatment
might be necessary. Moreover, the redundancy will probably not
be restricted to bFGF and VEGF. Hepatocyte growth factor serum
levels were also found to be above the cut-off value in 37% of 134
patients with a primary breast tumour (Taniguchi et al, 1995). A
therapeutical strategy that will inhibit more advanced steps in the
process of new vessel development might not have to deal with
this biological redundancy.
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